About ChulaBhorn Hospital
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Chulabhorn Cancer Center
2
Hoffmann-La Roche
2
Amgen
1
BeiGene
1
Chulabhorn Hospital
1
Odonate Therapeutics, Inc.
1
Singapore General Hospital
1
Vaccitech (UK) Limited
1
Clinical Trials at ChulaBhorn Hospital
During the past decade, ChulaBhorn Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
2010-07-01
2018-07-31
Unknown status
360
Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients
2016-05-01
2018-06-01
Completed
150
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
2017-12-21
2021-06-28
Terminated
685
Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy
2016-02-01
2018-03-01
Completed
120
Descriptors and Predictors of Burden and Information Needs
2019-10-01
2020-02-29
Completed
112
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
2019-12-31
2027-07-16
Active, not recruiting
668
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
2020-01-29
2025-09-19
Recruiting
400
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2021-03-31
2024-03-01
Recruiting
120
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "ChulaBhorn Hospital" #1 sponsor was "Chulabhorn Cancer Center" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials
sponsored, "Amgen" with 1 trials sponsored, "BeiGene" with 1 trials sponsored and "Chulabhorn Hospital"
with 1 trials sponsored. Other sponsors include -2 different institutions and
companies that sponsored additional 8 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "ChulaBhorn Hospital"
#1 collaborator was "National Cancer Centre, Singapore" with 1 trials as a collaborator, "National Medical Research Council (NMRC), Singapore" with 1 trials as a collaborator, "Singapore Clinical Research Institute" with 1 trials as a collaborator, "Sirtex Medical" with 1 trials as a collaborator and "University of Glasgow" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at ChulaBhorn Hospital
According to Clinical.Site data, the most researched conditions in "ChulaBhorn Hospital" are
"Adverse Effect of Radiation Therapy" (2 trials), "Breast Cancer" (2 trials), "Advanced Lung Cancer" (1 trials), "Breast Neoplasms" (1 trials) and "Carcinoma, Hepatocellular" (1 trials). Many other conditions were trialed in "ChulaBhorn Hospital" in a lesser frequency.
Clinical Trials Intervention Types at ChulaBhorn Hospital
Most popular intervention types in "ChulaBhorn Hospital" are "Drug" (6 trials), "Other" (4 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (3 trials), "Nivolumab" (2 trials), "Atezolizumab" (1 trials), "Bemarituzumab" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at ChulaBhorn Hospital
The vast majority of trials in "ChulaBhorn Hospital" are
10 trials for "All" genders.
Clinical Trials Status at ChulaBhorn Hospital
Currently, there are NaN active trials in "ChulaBhorn Hospital".
undefined are not yet recruiting,
4 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in ChulaBhorn Hospital,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in ChulaBhorn Hospital, 0 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".